| Autor: |
Ali, Mohammad Daud, Ahmad, Ayaz, Banu, Nuzhat, Patel, Munfis, Ghosn, Sherihan Ahmad, Eltrafi, Zainab |
| Předmět: |
|
| Zdroj: |
Journal of Pharmaceutical Health Services Research; Nov2020, Vol. 11 Issue 4, p411-414, 4p |
| Abstrakt: |
Objective: The study was aimed to evaluate the cost and drug utilization pattern of anticoagulant drugs in a clinical setting in Saudi Arabia. Method: A cross‐sectional retrospective study was conducted in a private hospital in Saudi Arabia. World Health Organization, defined daily dose, and American Society of Hematology methods were used to compute the daily price of each anticoagulant agent. Key findings: Consumption of oral anticoagulants was very less as compared to the parenteral. Apixaban was the most prescribed oral drug, while enoxaparin sodium was the drug of choice among the parenteral. In oral anticoagulants, the unit‐wise cost was found to be highest for Rivaroxaban (12.60 SR (3.36 USD) and less for Warfarin (0.82 SR (0.22 USD)). Heparin sodium cost (51.62 SR (13.76 USD) was found to be the most expensive parenteral agent while the least expensive was Phytomenadione (3.76 SR (1.00 USD)). Conclusion: Apixaban was the preferred oral anticoagulant among all the studied anticoagulants, although Warfarin is the cheapest. Therapeutic drug monitoring was recommended for Warfarin. The study highlights the importance of more studies to measure the advantages and disadvantages of all types of anticoagulants. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Plný text